Abstract
Myasthenia gravis (MG) is a rare, long‐term autoimmune disorder that causes muscle weakness; the condition typically has phases when it remits and phases when it relapses. Even though treatment response with regards to immunosuppressive therapies in MG patients is classically monitored by clinical scores, identification of a serological biomarker that monitors treatment response could be helpful. Here, the authors explore the correlation between acetylcholine receptor (AChR) antibody titers with changes in clinical severity in patients with MG and discuss the implications for clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
